{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:26:09Z","timestamp":1773271569355,"version":"3.50.1"},"reference-count":95,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>Cardiovascular diseases are still the most important cause of morbidity and mortality in western countries and antithrombotic treatment is nowadays widely used. Drugs able to reduce coagulation activation are the treatment of choice for a number of arterial and\/or venous thromboembolic conditions. Some of the drugs currently used for this purpose, such as heparins (UFH or LMWH) and VKA, have limitations consisting of a narrow therapeutic window and an unpredictable response with the need of laboratory monitoring in order to assess their efficacy and safety. These drawbacks have stimulated an active research aimed to develop new drugs able to act on single factors involved in the coagulation network, with predictable response. Intense experimental and clinical work on new drugs has focused on synthetic agents, which could preferably be administered orally and at fixed doses. The most advanced clinical development with new anticoagulants has been achieved for those inhibiting FXa and some of them, like fondaparinux, are already currently used in clinical practice. Other agents, such as rivaroxaban, apixaban, otamixaban and edoxaban are under development and have already been studied or are currently under investigation in large scale phase III clinical trials for prevention and treatment of venous thromboembolism, atrial fibrillation and acute coronary syndromes. Some of them have proved to be more effective than conventional therapy. Data on some agents inhibiting FVa are still preliminary and some of these drugs have so far been considered only in patients with disseminated intravascular coagulation secondary to sepsis.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2011.04001.x","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T11:21:27Z","timestamp":1304508087000},"page":"563-580","source":"Crossref","is-referenced-by-count":15,"title":["Inhibitors of propagation of coagulation: factors V and X"],"prefix":"10.1111","volume":"72","author":[{"given":"Vincenzo","family":"Toschi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242206"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106273242606"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0677"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0689"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371007"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685974"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781444306286.ch1"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00298.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4195"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01374.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1145260"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1145260"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.2174\/138955707780363819"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.16.1833"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.11.1337"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-11-200406010-00007"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"The Matisse Investigators","year":"2003","journal-title":"N Engl J Med"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912072"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055443"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.joc60038"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.789479"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1938"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.54"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1066023"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02943.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03089.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064247"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067703"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60168-3"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04100.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03746.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986707782023659"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61529-4"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61454-9"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.853119"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200948010-00001"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006292127"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02776.x"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-07-0434"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01602.x"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.642074"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01657.x"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60880-6"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa076016"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60734-0"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03618.x"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.957712"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.668020"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2009.05.004"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-160143"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02764.x"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810773"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62125-5"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006885"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03054.x"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.832139"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-07-0451"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03447.x"},{"key":"e_1_2_7_66_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1073.1073","article-title":"Pharmacokinetics of a new, ultra\u2010low molecular weight heparin, semuloparin (AVE5026), in healthy subjects. Results from the phase I studies. 51st ASH Annual Meeting","volume":"114","author":"Dubruc C","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03301.x"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753944710387808"},{"key":"e_1_2_7_69_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1160\/TH09-02-0105","article-title":"M118 \u2013 a rationally low\u2010molecular\u2010weight\u2010heparin designed specifically for the tratment of acute coronary syndromes","volume":"102","author":"Kishimoto TK","year":"2009","journal-title":"Thromb Hemost"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.913277"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-05-0234"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200948010-00001"},{"key":"e_1_2_7_73_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thrombo\u2010embolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie AGG","year":"2009","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.017"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.5"},{"key":"e_1_2_7_76_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.980.980","article-title":"An adaptive design dose\u2010ranging study of PD 0348292, a novel oral Factor Xa inhibitor, for the prophylaxis after total knee replacement study. 50th ASH Annual Meeting","volume":"112","author":"Cohen AT","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_77_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3153.3153","article-title":"Effects of direct factor Xa inhibitor, YM150, on clot formation and clot lysis in vitro compared with other anticoagulants. 49th ASH Annual Meeting","volume":"110","author":"Kaku S","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_78_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3155.3155","article-title":"Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in rodent venous and arterial thrombosis model. 49th ASH Annual Meeting","volume":"110","author":"Saitoh M","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_79_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.911.911","article-title":"Biochemical and pharmacological prophiles of YM150, an oral direct factor Xa inhibitor. 48th ASH Annual Meeting","volume":"108","author":"Iwatsuki Y","year":"2006","journal-title":"Blood"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02644.x"},{"key":"e_1_2_7_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03748.x"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-12-0817"},{"key":"e_1_2_7_83_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.4175.4175","article-title":"Absence of pharmacodynamic or pharmacokinetic interactions when TAK\u2010442, an oral direct factor Xa inhibitor, is coadministred with aspirin or clopidogrel. 51st ASH Annual Meeting","volume":"114","author":"Stringer F","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.04.005"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31820382a9"},{"key":"e_1_2_7_86_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0273"},{"issue":"1","key":"e_1_2_7_87_2","first-page":"S77","article-title":"Recombinant human activated protein C (RhAPC) improves coagulation abnormalities associated with severe sepsis","volume":"24","author":"Hartman DL","year":"1998","journal-title":"Intensive Care Ned"},{"key":"e_1_2_7_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441001"},{"key":"e_1_2_7_89_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc7936"},{"key":"e_1_2_7_90_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0656"},{"key":"e_1_2_7_91_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-009-1483-7"},{"key":"e_1_2_7_92_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-07-0468"},{"key":"e_1_2_7_93_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04375.x"},{"key":"e_1_2_7_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00927.x"},{"key":"e_1_2_7_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01251.x"},{"key":"e_1_2_7_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02267.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2011.04001.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2011.04001.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:14:25Z","timestamp":1694610865000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2011.04001.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1365-2125.2011.04001.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04001.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]}}}